Get the free version of Marbridge Daily delivered to your inbox

Click here to subscribe

Early-stage Cancer Detection Firm 'New Horizon Health' Wins USD 20 Mln Series A+

PE Daily, 8/09/17

Hangzhou-based early-stage cancer detection and analysis firm New Horizon Health Technology has completed USD 20 mln in Series A+ funding from Qiming Venture Partners, Legend Capital, SoftBank China Venture Capital, and computer software developer Pudu Technology.

New Horizon said that it plans to expand upon its line of early cancer screening products, particularly for gastro-intestinal cancer. The company will also look to collect and integrate big data with artificial intelligence technology, to develop the next generation of the company's early cancer screening technology.

New Horizon, established in November 2015, integrates gene detection with molecular diagnosis technology, and uses online software and big data technology to create an early cancer detection management system. The company's mission is to improve patients' chances of being cured, reduce medical costs, and improve medical efficiency.

The company has already developed a product that can be used at home which analyzes genetic material from stool samples to detect intestinal cancer in the early stages. The product can detect problems up to five years before any serious complications, and the early warning allows doctors to treat the problem through surgery.

Based on the company's intestinal cancer detection product, New Horizon this year released stomach cancer detection technology.

New Horizon Health CEO Zhu Yeqing said that the company has research centers in Beijing and Hangzhou, and also operates a medical testing laboratory. The company has marketing partnerships with online healthcare companies We Doctor Group, Almond Doctor, and Jiankang 160.

Keywords: New Horizon Health funding Series A VC Pudu M&A online healthcare Zhu Yeqing Internet Legend Capital Qiming Softbank China Venture Capital


Please note, all fields are required.
None of your personal information will be shared with third parties.



The information contained in this newsletter is based upon sources that Marbridge Consulting believes to be reliable, and we have made every effort to translate the original articles or article excerpts as faithfully as possible. However, Marbridge Consulting makes no warranty of and assumes no legal responsibility for the accuracy of either the original source material or the English language translations.

Marbridge Daily Premium

Interested in gaining full access to all newsletter articles and the Marbridge Daily archive? To learn more about premium subscription options, including pricing, please:

Click here

Marbridge Consulting RSS Feed

Marbridge Reports